Search Results
Because of You, We're Helping to Cure Cancer
Here at The Leukemia & Lymphoma Society (LLS), we remain laser-focused on continuing to drive forward our mission. In fact, we are amplifying our efforts to help patients and caregivers access the care they need, during the coronavirus crisis and beyond. Thankfully, we have a vibrant community of dedicated volunteers across the country who are just as relentless as we are about making a difference in the lives of blood cancer patients and their families.
Eight Years and Counting: "The Gray Zone"
If you want to get technical, I have cancer. At least I think I do. I was diagnosed eight years ago with chronic myeloid leukemia (CML) and while there are no longer any signs of disease in my bone marrow, this is a condition that never really goes away. The cancer-causing enzymes keep firing and my daily Gleevec pills continue pummeling them into submission. I like to think of myself as a cancer survivor, but dare I be so cocky? Not only do I not want to tempt fate, but it feels a bit like I’m staking claim to a territory I’m not fully entitled to.
Support at Your Fingertips: Try a Discussion Board
Having cancer can be a lonely experience, and it’s not always so easy to find others with a similar diagnosis. Even if you could, you might not always want to talk about everything face to face.
Sometimes an online discussion board is just what you need.
Going to School on Cancer
This blog is the second in a series.
Identification and characterization of genetic factors affecting MLL/KMT2A fusion proteins stability in MLL/KMT2A rearranged leukemias
MLL1/KMT2A rearranged leukemias are the most common blood cancer occurring in children characterized by dismal prognosis. Given the importance of fusion proteins in driving the disease, I will determine factors affecting the fusion protein stability through a CRISPR/Cas9 screening approach in an innovative model system where the MLL fusions are endogenously tagged with a fluorescent protein. This will facilitate development of molecular glue degraders specifically targeting the MLL fusions.Targeting Oncoembryonic Antigens ROR1 and ROR2 For Therapy Of Patients With Hairy Cell Leukemia
We will study the function of ROR1 and ROR2 on HCL cells that we have collected from 120 patients, examining whether they influence expression of genes that can promote the growth/survival of HCL cells. We have made antibodies that are highly specific for ROR1 or ROR2 that react with HCL cells, but not normal blood cells or tissues. We will determine if these antibodies can be used as naked antibodies, antibody-drug conjugates, or in chimeric receptors on T cells to specifically kill HCL cells.Alemtuzumab
Alemtuzumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL).
Bosutinib
Bosutinib is FDA approved for the treatment of
- Adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy.
- Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Filgrastim-sndz
Filgrastim-sndz is FDA approved as a biosimilar to US-licensed Neupogen® for the five indications for which Neupogen is approved:
- Patients with cancer receiving myelosuppressive chemotherapy;
- Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy;
- Patients with cancer undergoing bone marrow transplantation;
- Patients undergoing autologous peripheral blood progenitor cell collection and therapy; and
- Patients with severe chronic neutropenia.